[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1900
91. Flynn LW, Park J, Patil SM, Cody HS 3rd, Port ER: Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg; 2008 Apr;206(4):616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Men and women with breast cancer have similar risks of morbidity related to axillary lymph node dissection (ALND).
  • At a median followup of 28 months (range 5 to 96 months), there were no axillary recurrences.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Axilla. Breast Neoplasms / pathology. Child. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387465.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Arora N, Martins D, Huston TL, Christos P, Hoda S, Osborne MP, Swistel AJ, Tousimis E, Pressman PI, Simmons RM: Sentinel node positivity rates with and without frozen section for breast cancer. Ann Surg Oncol; 2008 Jan;15(1):256-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sentinel lymph node biopsy (SLNB) is used to detect breast cancer axillary metastases.
  • Some surgeons send the sentinel lymph node (SLN) for intraoperative frozen section (FS) to minimize delayed axillary dissections.
  • There has been concern that FS may discard nodal tissue and thus underdiagnose small metastases.
  • After adjustment for patient age, tumor diameter, grade, and hormone receptor status in a multivariate logistic regression model, there remained an increased likelihood of final node positivity for patients undergoing both procedures relative to PS alone (adjusted odds ratio, 2.1; 95% confidence interval, 1.3-3.6; P = .005).
  • Therefore, evaluating SLN by FS does not underdiagnose small metastases nor produce a higher false-negative rate.
  • Intraoperative FS offers the advantage of less delayed axillary dissections.
  • [MeSH-minor] Axilla. Female. Frozen Sections. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy / methods. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879116.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Barry M, Cahill RA, Roche-Nagle G, Landers R, Walsh D, Bouchier-Hayes DJ, Watson RG: Preoperative selection of symptomatic breast cancer patients appropriate for lymphatic mapping and sentinel node biopsy. Ir J Med Sci; 2007 Jul-Sep;176(2):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Breast ultrasound (US) and a simultaneous core biopsy was performed in all patients at their initial presentation, and their estimates of tumor size and grade compared with the final pathological specimen (FPS).
  • RESULTS: Of the T1 group 47% had lymphatic metastases as did 49% of those with grade I or II cancers.
  • By combining these measures, however, subgroups of patients with lower rates of nodal metastases were identified (32% of patients with T1, non-grade III disease had lymphatic disease while only 15% of those with T < 1.5 cm, non-grade III cancers had such metastases).
  • CONCLUSION: Combination of the US and ultrasound guided core biopsy (UGCB) may however identify subgroups unlikely to have axillary disease that are therefore suitable for SLNB.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Ultrasonography

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jan;82(2):381-4 [10646892.001]
  • [Cites] Ann Surg. 2003 May;237(5):732-8; discussion 738-9 [12724640.001]
  • [Cites] Arch Surg. 2003 May;138(5):482-7; discussion 487-8 [12742949.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1643-6 [8932348.001]
  • [Cites] Lancet. 1997 Jun 28;349(9069):1864-7 [9217757.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):705-10 [11597010.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):838-41; discussion 841-3 [12796580.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):29-31 [12559073.001]
  • [Cites] Br J Surg. 2002 Jan;89(1):21-34 [11851659.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):948-55 [9731899.001]
  • [Cites] Am J Surg. 2003 May;185(5):420-4 [12727560.001]
  • [Cites] Acta Oncol. 1999;38(3):295-303 [10380819.001]
  • [Cites] Eur J Surg Oncol. 2002 Aug;28(5):490-500 [12217300.001]
  • [Cites] J Med Screen. 1997;4(3):152-7 [9368873.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):351-4 [11720669.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Am J Surg. 2003 May;185(5):425-8 [12727561.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):350-3 [8293399.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Surg Oncol. 1993 Dec;2(6):335-9; discussion 340 [8130940.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):432-7 [11407518.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):377-83 [11720675.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • (PMID = 17476566.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


9
Advertisement
4. Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK: Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer; 2007 Apr 1;109(7):1255-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
  • However, a relative contraindication to SLN biopsy after preoperative chemotherapy is the presence of axillary metastases at initial diagnosis.
  • The objective of this study was to determine the feasibility and accuracy of SLN biopsy after preoperative chemotherapy in patients with documented axillary metastases at presentation.
  • METHODS: Between 1994 and 2002, 69 patients who had axillary metastases identified by ultrasound-guided, fine-needle aspiration underwent SLN biopsy after treatment on prospective, preoperative chemotherapy protocols.
  • All but 8 patients underwent axillary lymph node dissection (ALND).
  • RESULTS: The median patient age was 49 years, and the median primary tumor size was 4 cm.
  • Based on the current results, the status of the SLN cannot be used as a reliable indicator of the presence or absence of residual disease in the axilla in this patient population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla / pathology. Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. False Negative Reactions. Feasibility Studies. Female. Fluorouracil / therapeutic use. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Preoperative Care. Time Factors. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17330229.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CAF protocol; FEC protocol
  •  go-up   go-down


95. Khera SY, Kiluk JV, Hasson DM, Meade TL, Meyers MP, Dupont EL, Berman CG, Cox CE: Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J; 2008 May-Jun;14(3):250-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positive SLN were identified in 5/10 patients (50%) while there was no evidence of metastases in 5/10 patients (50%).
  • By performing a SLN biopsy, a large proportion of patients with PABC may be spared the risk of a complete axillary lymph node dissection.
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Maternal Exposure. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies


96. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res; 2005 Aug 15;11(16):5686-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
  • PURPOSE: The chemokine receptors CCR7 and CXCR4 have been shown to play an important role in cancer metastasis.
  • We therefore studied the differential expression of CCR7 and CXCR4, along with that of the biomarker HER2-neu, to evaluate whether these biomarkers could predict axillary lymph node metastasis in breast cancer.
  • CONCLUSIONS: Our results suggest that the chemokine receptor CCR7 is a novel biomarker that can predict lymph node metastases in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Lymph Nodes / pathology. Receptors, CXCR4 / analysis. Receptors, Chemokine / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Predictive Value of Tests. Receptor, ErbB-2 / analysis. Receptors, CCR7

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115904.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCR7 protein, human; 0 / Receptors, CCR7; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


97. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G: Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol; 2005 Mar 1;23(7):1379-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
  • BACKGROUND: Overt ipsilateral axillary lymph node metastases of breast cancer are the most significant prognostic indicators for women who have undergone surgery, yet the clinical relevance of minimal involvement (isolated tumor cells and micrometastases) of these nodes is uncertain.
  • At the multivariate analysis, a statistically significant difference in disease-free survival (DFS) and in the risk of distant metastases was observed for patients with pN1a versus pN0 disease (hazard ratio [HR] = 2.04; 95% CI, 1.46 to 2.86; P < .0001 for DFS; HR = 2.32; 95% CI, 1.42 to 3.80; P = .0007 for distant metastases) and for patients with pN1mi/pN0i+ versus pN0 disease (HR = 1.58; 95% CI, 1.01 to 2.47; P = .047 for DFS; HR = 1.94; 95% CI, 1.04 to 3.64; P = .037 for distant metastases).
  • CONCLUSION: Even minimal involvement of a single axillary node in breast cancer significantly correlates with worse prognosis compared with no axillary node involvement.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Axilla. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735114.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Yirmibeşoğlu E, Tekin E, Memiş L, Yamaç D, Taneri F, Erkal HS: A patient with occult breast cancer presenting with an axillary lymph node metastasis and a synchronous contralateral breast cancer. Breast; 2005 Apr;14(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with occult breast cancer presenting with an axillary lymph node metastasis and a synchronous contralateral breast cancer.
  • Detection of a breast mass accompanied by a contralateral axillary lymphadenopathy presents a dilemma because of the possible presence of an occult breast cancer on the same side as the axillary lymphadenopathy.
  • A patient presented with an axillary lymphadenopathy from an occult breast cancer and a synchronous contralateral breast cancer, for which the differential diagnosis was established through a significant difference in estrogen and progesterone receptor levels.
  • She is alive and free of disease 1.5 years after the diagnosis.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphatic Metastasis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Axilla. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Functional Laterality. Humans. Mastectomy, Modified Radical. Middle Aged. Neoadjuvant Therapy. Neoplasms, Unknown Primary. Postmenopause. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767187.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


99. Dian D, Straub J, Scholz C, Mylonas I, Rack B, Sommer H, Janni W, Friese K: Influencing factors for regional lymph node recurrence of breast cancer. Arch Gynecol Obstet; 2008 Feb;277(2):127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: We conclude from these data that women who have negative nodal status at surgical staging do not benefit from further systematic axillary resection with regard to regional lymph node recurrence.
  • For those women, however, who have confirmed axillary metastasis, systematic axillary resection lowers the risk of regional lymph node recurrence depending on the number of lymph nodes removed.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Estrogen Antagonists / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Mastectomy, Segmental. Middle Aged. Multivariate Analysis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763863.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Antagonists
  •  go-up   go-down


100. Straver ME, Rutgers EJ, Oldenburg HS, Wesseling J, Linn SC, Russell NS, Vrancken Peeters MJ: Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy. Am J Surg; 2009 Jul;198(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.
  • BACKGROUND: Recently, lower axillary lymph node retrieval after neoadjuvant chemotherapy was reported.
  • We did not have this experience, and retrospectively analyzed our axillary lymph node dissections (ALNDs).
  • In the neoadjuvant group, 150/191 (79%) patients had residual lymph node metastasis after neoadjuvant chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Axilla. Biopsy, Fine-Needle. Bridged Compounds / therapeutic use. Feasibility Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Mastectomy / methods. Middle Aged. Reproducibility of Results. Retrospective Studies. Taxoids / therapeutic use. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095215.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down






Advertisement